CLINICAL TRIAL

A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2025-10-29
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

Anna Rose Childress Ph.D.

Watch author

Derived topics and classifications

psilocybin Depression Addiction OCD Receptor Pharmacology Consciousness Biomarkers Emotional Processing Spirituality Mystical Experience Clinical Trial Observational Study Safety Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in LifeClinicalTrials.gov · 2026-08-17 Psychedelics and Psychedelic-Assisted Psychotherapy.The American journal of psychiatry · 2020-05-01 Psychedelics and Psychedelic-Assisted Psychotherapy.Focus (American Psychiatric Publishing) · 2021-01-01